Cardioprotection thread, page-661

Thanks for the balanced reply.
One of the big issues with retail investors in the bio sector is that they have a one eyed view, for instance the majority will only invest in one company in the oncology or neurological disorder area and pin their hopes on it alone instead of realizing there are other companies out there, multiple can succeed, not just one, the opposite seems to be the norm in the mining or finance sector; they’ll invest in multiple stocks looking for gold for instance; go figure.
I monitor with great interest, diversity is the name of the game.